PSMB3抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Jurkat cell lysate, Primary antibody: P02857(PSMB3 Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P02857(PSMB3 Antibody) at dilution 1/150. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P02857(PSMB3 Antibody) at dilution 1/150. (Original magnification: ×200)    

  
  

The PSMB3 (Proteasome 20S Subunit Beta 3) antibody is a research tool targeting the PSMB3 protein, a critical component of the 20S core particle of the proteasome. The proteasome is a multi-subunit protease complex responsible for degrading ubiquitinated proteins, regulating cellular processes like cell cycle progression, stress responses, and antigen presentation. PSMB3. encoded by the PSMB3 gene, is one of seven beta subunits forming the proteolytic chamber of the 20S proteasome, exhibiting caspase-like (trypsin-like) activity. Its expression is constitutive but can be upregulated under stress or in immune cells as part of the immunoproteasome.

Antibodies against PSMB3 are widely used to study proteasome composition, dynamics, and dysfunction in diseases such as cancer, neurodegenerative disorders, and autoimmune conditions. They enable detection of PSMB3 via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), aiding in investigations of proteasome activity alterations during pathogenesis. For instance, PSMB3 dysregulation has been linked to tumor progression and drug resistance, making it a potential biomarker or therapeutic target. These antibodies also help evaluate the efficacy of proteasome inhibitors (e.g., bortezomib) in cancers like multiple myeloma.

Developed in various host species (e.g., rabbit, mouse), PSMB3 antibodies are validated for specificity, often through knockout controls or siRNA knockdown. Their applications span basic research on protein turnover mechanisms to translational studies in disease models.